Gilbert Cisneros Buys Vaxcyte, Inc. Shares

Congressman Gilbert Cisneros purchased shares of Vaxcyte, Inc. valued between $1,001 and $15,000.

Written by Trueearnings · Published Jun 13, 2026, 2:10 AM EDT · Updated Jun 14, 2026, 8:01 PM EDT

Key Points

Gilbert Cisneros, a member of the House, bought Vaxcyte, Inc. shares valued between $1,001 and $15,000, reported on June 9, 2026.
Vaxcyte, Inc. shares are trading at $47.46 with a market cap of $6.85 billion and a beta of 1.242.
Institutional investors like Janus Henderson and FMR LLC have also increased their stakes in Vaxcyte recently.

Congressional trading track record

Gilbert Cisneros vs. the S&P 500

YTD return -1.4% hypothetical

All-time return -1.0% S&P 500 +93.0%

vs. S&P 500 -94.0% behind the index

Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.

On June 9, 2026, Congressman Gilbert Cisneros disclosed a purchase of Vaxcyte, Inc. shares valued between $1,001 and $15,000. This transaction was reported after the trade, which took place on May 12, 2026. Cisneros, a member of the House of Representatives, showed interest in the biotechnology company that is currently trading at $47.46 per share.

Other Institutional Activity in Vaxcyte

In addition to Cisneros's purchase, several institutional investors have made moves with Vaxcyte stock. Janus Henderson Group PLC grew its holdings by 3,188,687 shares, ending with 16,575,875 shares valued at approximately $960.2 million. FMR LLC also increased its position by 2,658,347 shares, bringing its total to 16,492,861 shares worth about $958.4 million. T. Rowe Price Investment Management, Inc. added 829,684 shares, now holding 12,126,017 shares valued at $704.6 million.

Vaxcyte Stock Snapshot

Vaxcyte, Inc. (NasdaqGS: PCVX) is trading at $47.46, with a market capitalization of $6.85 billion. The company has a forward P/E ratio that is not meaningful as it isn't currently profitable. Its beta, a measure of volatility, stands at 1.242. Over the past year, the stock has ranged from a low of $29.08 to a high of $65.00. The 50-day moving average is $54.48, while the 200-day moving average is $48.67. Vaxcyte maintains a strong financial position with a current ratio of 7.49 and a quick ratio of 7.18.

Recent Earnings

Vaxcyte reported its latest earnings on May 6, 2026. The company is still in the clinical stage and has not yet generated revenue. Its earnings per share were negative at -$6.89, reflecting ongoing investment in research and development. Vaxcyte's return on equity is -30.55%, indicating the challenges of funding its innovative vaccine pipeline.

Insider Buying and Selling at Vaxcyte, Inc.

Several insiders have been active in trading Vaxcyte shares. Jim Wassil, the Chief Operating Officer, sold 2,250 shares on June 1, 2026, at an average price of $49.52, as part of a planned sale. Previously, Wassil sold additional shares on May 1 and April 1. Elvia Cowan, SVP of Finance & CAO, also executed trades, selling 3,000 shares on April 7 at $60.00, while buying 3,000 shares at $25.92 on the same day.

Analysts Set New Price Targets

Analysts remain optimistic about Vaxcyte's potential. On February 26, 2026, BTIG maintained a buy rating with a price target of $89. Guggenheim reiterated its buy rating with a target of $116 on February 2, 2026. The consensus among analysts is a strong buy, with a mean price target of $109, based on nine analyst opinions.

About Vaxcyte, Inc.

Vaxcyte, Inc. is a biotechnology company focused on developing vaccines to prevent bacterial infections. Headquartered in San Carlos, California, the company is led by CEO Grant E. Pickering. Vaxcyte's lead product is VAX-24, a pneumococcal conjugate vaccine aimed at preventing invasive pneumococcal disease. The company is also developing other vaccine candidates targeting various bacterial pathogens.

Bottom Line

Gilbert Cisneros's purchase of Vaxcyte shares highlights ongoing interest in the company's potential. Vaxcyte is a clinical-stage biotech firm with a promising vaccine pipeline, though it remains unprofitable. Institutional investors and analysts show strong interest, reflecting confidence in Vaxcyte's future prospects. Remember, these trades are disclosed after the fact and may not reflect current positions.